Celldex Therapeutics (CLDX) Operating Leases (2019 - 2026)

Celldex Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $443000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 77.03% year-over-year to $443000.0; the TTM figure through Mar 2026 stood at $443000.0 (down 77.03% YoY), while the FY2025 annual figure was $784000.0, down 66.79% from the prior year.
• Operating Leases for Q1 2026 stood at $443000.0, down from $784000.0 in the prior quarter.
• The five-year high for Operating Leases was $2.6 million in Q4 2022, with the low at $443000.0 in Q1 2026.
• The 5-year median for Operating Leases is $1.5 million (2025), against an average of $1.5 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases tumbled 78.21% in 2024, then soared 310.43% in 2025.
• Celldex Therapeutics' Operating Leases stood at $2.6 million in 2022, then tumbled by 64.14% to $928000.0 in 2023, then surged by 154.42% to $2.4 million in 2024, then tumbled by 66.79% to $784000.0 in 2025, then tumbled by 43.49% to $443000.0 in 2026.
• Business Quant data shows CLDX's Operating Leases at $443000.0 in Q1 2026, $784000.0 in Q4 2025, and $1.1 million in Q3 2025.